Search Result

Results for "

insulinotropic agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Dipeptidyl Peptidase (3) Drug Derivative (1) Insulin Receptor (1) Isotope-Labeled Compounds (3) Potassium Channel (13) Reference Standards (3)
By Research Areas:	Inflammation/Immunology (1) Metabolic Disease (16)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0422

Nateglinide A4166; Senaglinide	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-B0682A

Mitiglinide calcium hydrate 2 Publications Verification KAD-1229; S-21403	Potassium Channel	Metabolic Disease
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-17398

Mitiglinide calcium 2 Publications Verification KAD-1229 anhydrous; S21403 anhydrous	Potassium Channel	Metabolic Disease
Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INA-X 14; Insulin X 14	Insulin Receptor Drug Derivative	Metabolic Disease
Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research .

HY-B0682

Mitiglinide KAD-1229 free acid anhydrous; S21403 free acid anhydrous	Potassium Channel	Metabolic Disease
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-B0422S

Nateglinide-d5 A4166 d₅; Senaglinide d₅	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-126198A

Linogliride fumarate McN-3935 fumarate	Antibiotic	Metabolic Disease
Linogliride (MCN-3935) fumarate is an antidiabetic agent. Linogliride fumarate (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .

HY-126198

Linogliride McN-3935	Antibiotic	Metabolic Disease
Linogliride (MCN-3935) is an antidiabetic agent. Linogliride (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .

HY-B0422R

Nateglinide (Standard) A4166 (Standard); Senaglinide (Standard)	Potassium Channel Dipeptidyl Peptidase Reference Standards	Metabolic Disease
Nateglinide (Standard) is the analytical standard of Nateglinide. This product is intended for research and analytical applications. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-B0682S2

Mitiglinide-d5 calcium	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-B0682S1

(2R)-Mitiglinide-d5 calcium	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-17398R

Mitiglinide calcium (Standard) KAD-1229 anhydrous (Standard); S21403 anhydrous (Standard)	Potassium Channel Reference Standards	Metabolic Disease
Mitiglinide (calcium) (Standard) is the analytical standard of Mitiglinide (calcium). This product is intended for research and analytical applications. Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .

HY-B0682AR

Mitiglinide calcium hydrate (Standard) KAD-1229 (Standard); S-21403 (Standard)	Reference Standards Potassium Channel	Metabolic Disease
Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-W777434

Mitiglinide calcium hydrate-d8	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Mitiglinide (calcium hydrate)-d₈ is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-B0682S

Mitiglinide-d8 calcium hydrate	Potassium Channel	Metabolic Disease
Mitiglinide-d₈ calcium hydrate (KAD-1229-d₈) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-19174

BTS-67582	Potassium Channel	Metabolic Disease Inflammation/Immunology
BTS-67582 is an orally active nonsulfonylurea *insulinotropic* agent and potassium channel blocker. BTS-67582 affects the K ⁺ ATP channel in the islet cell but at a different binding site than the sulfonylureas. BTS-67582 is an antidiabetic agent .

Cat. No.	Product Name	Target	Research Area

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INA-X 14; Insulin X 14	Insulin Receptor Drug Derivative	Metabolic Disease
Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research .

Cat. No.	Product Name	Chemical Structure

HY-B0422S

Nateglinide-d5
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-B0682S2

Mitiglinide-d5 calcium
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-B0682S1

(2R)-Mitiglinide-d5 calcium
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-W777434

Mitiglinide calcium hydrate-d8
Mitiglinide (calcium hydrate)-d₈ is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

Mitiglinide calcium hydrate-d8

Mitiglinide (calcium hydrate)-d₈ is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-B0682S

Mitiglinide-d8 calcium hydrate
Mitiglinide-d₈ calcium hydrate (KAD-1229-d₈) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

Mitiglinide-d8 calcium hydrate

Mitiglinide-d₈ calcium hydrate (KAD-1229-d₈) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.